Navigation Links
BioNeutral Group's CEO, Stephen Browand and Chief Scientist, Dr. Andrew Kielbania to Appear on WVOX 1460 AM 'In Focus' Radio Show Hosted by Dr. Dan Miller
Date:7/29/2009

lude natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.

More information about the Company may be found at www.bioneutralgroup.com.

Forward-Looking Statements

BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.

Contact Information

    BioNeutral Group Inc.
    Stephen J. Browand, President and CEO
    steve@bioneutralgroup.com

    Investor Relations
    Aimee Boutcher
    973 239-2878
    aboutcher@aol.com


'/>"/>
SOURCE BioNeutral Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms
3. BioNeutrals Ygiene(TM) Hospital Grade Antimicrobial Demonstrates a 99.9997% Kill Rate Against Clostridium Difficile Spores (C.diff) in Independent Lab Pre-testing Phase
4. BioNeutral Signs Agreement With a Non-profit for Long-Term Removal of Formaldehyde to Save 10,000 Mobile Homes in Louisiana
5. BioNeutrals Ygiene(TM) New Hospital Grade Disinfectant Will Save Lives and Billions of Dollars Annually at Health Care Facilities Around the World
6. BioNeutral Laboratories Announces the Appointment of Stephen Browand as a Director to Head Military, Homeland Security and Governmental Affairs
7. BioNeutral Announces a BREAKTHROUGH in the Fight Against Bioterrorism
8. Disabled and other vulnerable groups more susceptible to terrorism fears
9. DFG establishes 14 new research training groups
10. Disabled and other vulnerable groups more susceptible to terrorism fears
11. ChemAxon Launches Marvin and JChem Version 5.2; Web Services, native .NET API, Homology Groups, 3D Alignment and Structural Frameworks
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 2National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 3National Instruments and DENSO Robotics Collaborate to Address New Applications in Industrial Robotics 4Rodent smoke screen 2Superior offspring without genetic modification 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 1Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 2Eastern Europes First Novalis Tx 28TM 29 Radiosurgery Platform Begins Radiotherapy Treatments in Latvia using RapidArc 28R 29 Technology 5467 3National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 1National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 2National Intrepid Center of Excellence To Combat Traumatic Brain Injury With Sophisticated Brain Mapping Technology From Elekta 5462 3ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 1ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 2ZyStor Therapeutics Inc Cleared to Begin Clinical Trial for Targeted Protein Therapeutic for the Treatment of Pompe Disease 5457 3